CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults
Go back to CDC ACIP Unanimously Votes to Recommends Merck's (MRK) VAXNEUVANCE in Series with PNEUMOVAX as Option for Pneumococcal Vaccination in Appropriate Adults| Merck & Co. (NYSE: MRK) | Delayed: 120.76 +1.67 (1.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $119.09 | 52 Week High | $65.46 | |||
| Open | $120.04 | 52 Week Low | $47.97 | |||
| Day High | $122.71 | P/E | 82.15 | |||
| Day Low | $119.95 | EPS | $1.47 | |||
| Volume | 13,179,179 | |||||
